Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia

Journal of Nuclear Medicine

Volumn 40, Issue 11, 1999, Pages 1935-1946

  Sgouros, George ^a   Ballangrud, Åse M ^b   Jurcic, Joseph G ^b   McDevitt, Michael R ^b   Humm, John L ^b   Erdi, Yusuf E ^b   Mehta, Bipin M ^b   Finn, Ronald D ^b   Larson, Steven M ^b   Scheinberg, David A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

particle; 213Bi; HUM195; Leukemia; Radioimmunotherapy

Indexed keywords

BISMUTH; BISMUTH 213; CD33 ANTIGEN; MONOCLONAL ANTIBODY M 195; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANTIBODY LABELING; ARTICLE; DOSIMETRY; DRUG ABSORPTION; DRUG HALF LIFE; ELECTRON; HUMAN; LEUKEMIA; LINEAR ENERGY TRANSFER; PHOTON; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE DECAY;

ACUTE DISEASE; ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BISMUTH; GAMMA CAMERAS; HUMANS; LEUKEMIA, MYELOID; MICE; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE;

EID: 0032694040     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986;27:1490-1497.
2. Sgouros G. Radioimmunotherapy of micrometastases. In: Riva P, ed. Cancer Radioimmunotherapy: Present and Future. Harwood Academic Publishers; 1998: 191-207.
3. Larson SM, Sgouros G, Cheung NKV. Monoclonal antibodies in cancer therapy: radioisotope conjugates. In: Devita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. 2nd ed. Philadelphia, PA: Lippincott; 1995:534-552.
4. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1987;13:1767-1773.
5. Humm JL, Chin LM. A model of cell inactivation by alpha-particle internal emitters. Radiat Res. 1993;134:143-150.
6. Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA. 1986;83:474-478.
7. 212Bi linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst. 1988;80:449-452.
8. Macklis RM, Kinsey BM, Kassis Al, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240:1024-1026.
9. Harrison A, Royle L. Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma. NCI Monogr. 1987;3:157-158.
10. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R, Wolf AP. The in vitro radiobiology of astatine-211 decay. Radiat Res. 1986;105:27-36.
11. Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab′)2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA. 1989;86:7149-7153.
12. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 1994;54:4719-4725.
13. Geerlings MW. Radionuclides for radioimmunotherapy: criteria for selection. Int J Biol Markers. 1993;8:180-186.
14. 225Ac-immunoconjugates. Nucl Med Commun. 1995;16: 468-476.
15. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341-1351.
16. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isotopes. 1999;50:895-904.
17. Nikula TK, McDevitt MR, Finn RD, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999;40:166-176.
18. Jurcic JG, McDevitt MR, Sgouros G, et al. Targeted alpha-particle therapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33) [abstract]. Blood. 1997; 90(suppl):504a.
19. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia. 1989;3:440-445.
20. Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3:339-348.
21. Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994;83:1760-1768.
22. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9:478-490.
23. 131I labeled monoclonal antibody M195 for acute myelogenous leukemia (AML). J Clin Oncol. 1993;11:294-303.
24. Sgouros G, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med. 1993;34:422-430.
25. Junghans RP, Sgouros G, Scheinberg DA. Antibody-based immunotherapies for cancer. In: Chabner B, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. 2nd ed. Philadelphia, PA: Lippincott; 1996:655-689.
26. Cole A. Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiat Res. 1969;38:7-33.
27. Browne E, Firestone RB, Shirley VS. Table of Radioactive Isotopes. New York, NY: John Wiley & Sons; 1986.
28. Sgouros G, Humm JL, McDevitt M, et al. Bisumth-213 imaging: pre-clinical characterization of an alpha-particle emitting radionuclide [abstract]. J Nucl Med. 1996;37:78P-79P.
29. Jaszczak RJ, Greer KL, Floyd CE Jr, Harris CC, Coleman RE. Improved SPECT quantification using compensation for scattered photons. J Nucl Med. 1984;25:893-900.
30. Koral KF, Wang X, Rogers WL, Clinthorne NH, Wang X. SPECT: Compton-scattering correction by analysis of energy spectra. J Nucl Med.1988;29:195-202.
31. Hubbell JH, Seltzer SM. Tables of x-ray mass attenuation coefficients and mass energy-absorption coefficients I keV to 20 MeV for elements Z = 1 to 92 and 48 additional substances of dosimetric interest. National Institute of Standards and Technology 5632, Web version 1.02, 1997. Available at: http://www.physics.nist. gov/PhysRefData/XrayMassCoef/cover.html. Accessed October 12, 1999.
32. International Commission on Radiological Protection. Report of the Task Group on Reference Man. ICRP publication 23. New York, NY: Pergamon Press; 1975:86-91.
33. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York, NY: Society of Nuclear Medicine; 1989.
34. Snyder WS, Ford MR, Warner GG. Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. MIRD pamphlet no. 5, rev ed. New York, NY: Society of Nuclear Medicine; 1978.
35. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997; 80(suppl):2505-2509.
36. Erdi YE, Wessels B, Loew M, Erdi A. Threshold estimation in single photon emission computed tomography (SPECT) and planar imaging for clinical radioimmunotherapy. Cancer Res. 1995;55(suppl):5823s-5826s.
37. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res. 1991;128:204-209.
38. Snyder W, Ford M, Warner G, Watson S. 'S' Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD pamphlet no. 11. New York, NY: Society of Nuclear Medicine; 1975.
39. Larson SM, Nelp WB. The radiocolloid bone marrow scan in malignant disease. J Surg Oncol. 1971;3:685-697.
40. Simons RJB. Passive transport and binding of lead by human red blood cells. J Physiol. 1986;378:267-286.